#AbbVie

Several makers of hepatitis C drugs are limiting health care providers’ access to the 340B Drug Pricing Program’s discounts.

Drugmaker AbbVie teams with Michigan’s Department of Corrections and Department of Health and Human Services to launch “We Treat Hep C.”

A recent study of the direct-acting antiviral regimen included people who contracted hep C within the previous 12 months.

Researchers analyzed PPIs’ potential effects on nearly 2,400 participants of nine studies of Mavyret.

The approval applies to those between 12 and 17 years old who have any of the six genotypes of the virus.

Are subscription treatment models the future of hepatitis C treatment?

These drugs are approved to treat all six major genotypes of hepatitis C.

Stop me if you’ve heard this one before.

A review of the major findings presented at the Annual Meeting of the American Association for the Study of Liver Diseases in San Francisco

Nearly all those treated in a recent trial were cured.

The study population included those with all hepatitis C genotypes—except genotype 3.

A recent analysis of two studies of AbbVie’s hepatitis C regimen showed good results in this population.

The annual scientific meeting on liver health revealed exciting new findings concerning the battle against the hep C epidemic.

Nearly all those who have recently completed treatment in an Italian cohort are apparently poised for a cure.

A recent study analyzed kidney parameters among those with HIV who were treated for hep C with the regimen.